RVTY

Business profile & competitive position

Revvity, Inc. is a health science solutions company operating in the Healthcare sector, specifically the Medical – Diagnostics & Research industry. It provides technologies, expertise and services across workflows from discovery through development and from diagnosis to cure. The company is organized into two segments. The Life Sciences segment supplies reagents, instruments, software and services that accelerate drug discovery and development, while the Diagnostics segment provides instruments, reagents, assay platforms and software focused on reproductive health, immunodiagnostics and emerging-market diagnostics. Revvity markets its products and services in more than 160 countries from its headquarters in Waltham, Massachusetts.

Its financial returns, however, do not read like those of a classic wide-moat compounder. The trailing net margin is 8.2% and return on equity is 3.3%. Those figures are positive, but they are relatively modest for a company carrying a forward-looking valuation premium. Rather than signaling a deeply entrenched pricing advantage, the numbers suggest Revvity’s competitive position rests more on specialized workflow integration, regulatory-cleared assays, customer stickiness in diagnostics labs, and recurring consumable revenue on installed instruments. The fairly low ROE also hints that capital intensity—R&D, acquisitions and global distribution—continues to absorb a meaningful share of earnings. The bull case, therefore, is not that margins are currently dominant; it is that the breadth of the platform, spanning multi-omics, imaging and informatics, could translate into more durable revenue streams if adoption scales and operating leverage materializes.

Financial posture

As of the current snapshot, Revvity’s market capitalization is $16.7 billion, the stock price is $149.53, and the P/E ratio is 71.2. That multiple is steep relative to the 8.2% net margin and 3.3% ROE, implying the market is pricing in above-average growth or a meaningful inflection in profitability rather than the current return profile. The beta is 1.09, meaning the stock has historically moved slightly more than the broader market, which is consistent with a mid-cap healthcare name with both defensive revenue and growth-investor exposure.

From a technical standpoint, the price sits well above the 50-day EMA of $127.47, and the RSI is 71.3. An RSI above 70 conventionally indicates the stock is technically overbought, although that framing alone does not predict a reversal. What is clear is that price momentum has been strong, and the valuation leaves little room for disappointment on execution or guidance.

Strategic priorities & outlook

Revvity’s most recent 10-K filing outlines four near-term priorities that drive management’s capital and operating decisions.

• Strengthen key markets by expanding global product and service offerings, maintaining product quality, and improving the customer experience.
• Accelerate transformational innovation through internal R&D, third-party collaborations, and strategic acquisitions or licensing.
• Advance the use of Artificial Intelligence to differentiate offerings and improve internal operating efficiency.
• Maintain disciplined capital allocation to support organic investment, M&A, and opportunistic share repurchases.

Operationally, the company employed approximately 11,000 people as of December 28, 2025, including roughly 2,000 sales and service representatives in about 40 countries. Products are marketed mainly through specialized sales forces, with distributors filling gaps where the company lacks a direct presence. The filing also flags a supply-chain reality common in diagnostics and life sciences: certain principal products rely on a limited or single qualified source for critical raw materials and components, and Revvity periodically pre-purchases inventory ahead of manufacturing needs. That single-source exposure is a recurring operational risk, even if it has not yet disrupted the reported earnings streak.

Macro & geopolitical exposure

Because Revvity sits in Medical – Diagnostics & Research, its exposures follow the typical risk map for the industry rather than any company-specific factor. Regulatory clearance and reimbursement are central: products sold in Europe must comply with the In Vitro Diagnostic Regulation (IVDR), and U.S. diagnostics face FDA oversight and payor pricing pressure. The company’s 160-country footprint means currency translation can swing reported results, while tariffs, export controls, and logistics disruptions can affect instrument and reagent shipments. Public-health funding cycles, from government newborn-screening programs to biopharma R&D budgets, directly influence demand for both the Diagnostics and Life Sciences segments. Finally, the broader M&A environment matters: Revvity’s strategy explicitly relies on acquisitions and licensing, so financing costs and antitrust scrutiny can accelerate or constrain that growth lever.

Recent developments

The most recent news flow has centered on Type 1 diabetes testing in Europe. On September 25, 2026, Zacks reported that Revvity launched a new kit in Europe for newborn Type 1 diabetes detection. One day earlier, on September 24, 2026, BusinessWire announced that Revvity had launched an IVDR-certified solution for early detection of Type 1 diabetes. The repeated emphasis on IVDR certification matters because it signals that Revvity has navigated the more stringent European regulatory pathway and can now market the assay broadly across the EU.

Also on September 24, 2026, DefenseWorld published a side-by-side company review comparing Codexis (NASDAQ:CDXS) and Revvity (NYSE:RVTY), and separately reported that State Street Corp acquired RVTY shares. Institutional accumulation is a useful data point for understanding ownership trends, though it does not by itself imply a directional recommendation.

Earnings behavior & post-earnings drift

Revvity’s earnings track record has been flawless over the last eight reported quarters: 8 of 8 beats, with an average earnings surprise of 7.2%. Yet the stock’s reaction to those beats has been uneven. The average 5-day post-earnings move across those quarters is just 0.8%, classified as a mild upward drift. That low average masks larger individual moves.

In the most recently reported quarters, the pattern is clearly mixed. On August 4, 2026, Revvity reported EPS of $1.41 versus the consensus estimate of $1.21, a 16.5% surprise. The stock rose 3.26% the next day and 3.9% over the following five days. On May 5, 2026, actual EPS was $1.06 against an estimate of $1.02, a 3.9% surprise, and the stock jumped 7.36% the next day and 7.58% over five days. By contrast, the prior two reports saw selling pressure despite beats. On February 2, 2026, EPS of $1.70 beat the $1.57 estimate by 8.3%, yet the stock fell 5.57% the next day and 3.99% over five days. On October 27, 2025, EPS of $1.18 beat the $1.14 estimate by 3.5%, and the stock slipped 0.73% the next day and 4.31% over five days.

The takeaway is that beating estimates has become the baseline expectation, not the catalyst. With the next earnings release scheduled for October 26, 2026, before the market open, and the consensus EPS estimate at $1.28, the focus is likely to be on guidance, order commentary, and whether management can reignite the magnitude of post-earnings drift seen earlier in 2026.

For a deeper dive into how institutional analysts are interpreting Revvity’s valuation, earnings setup and strategic direction ahead of the October 26 report, review the full institutional verdict on the platform.